Antibody Response to COVID-19 Vaccines in Liver Disease Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04775069|
Recruitment Status : Recruiting
First Posted : March 1, 2021
Last Update Posted : May 25, 2021
|Condition or disease||Intervention/treatment||Phase|
|Chronic Liver Disease||Biological: BNT162b2 Biological: CoronaVac Biological: AZD1222||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||900 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective Study Comparing the Antibody Response of Subjects With Chronic Liver Disease to mRNA, Inactivated Virus and Adenovirus Vector COVID-19 Vaccines|
|Actual Study Start Date :||May 21, 2021|
|Estimated Primary Completion Date :||December 31, 2021|
|Estimated Study Completion Date :||March 31, 2022|
Active Comparator: mRNA Group
The subjects will be vaccinated with the mRNA vaccine (Pfizer-Biontech).
Active Comparator: Inactivated Virus Group
The subjects will be vaccinated with inactivated SARS Cov-2 (Sinovac).
Active Comparator: Adenovirus-vector Group
The subjects will be vaccinated with adenovirus-vector COVID-19 vaccine (Astrazeneca-Oxford).
- Antibody response [ Time Frame: at 4 weeks after second dose ]Covid-19 Antibodies IgG titres at 4 weeks after second dose
- Antibody response [ Time Frame: at one year after second dose ]Covid-19 Antibodies IgG titres at one year after second dose
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04775069
|Humanity & Health Medical Group Limited||Recruiting|
|Hong Kong, Hong Kong|
|Contact: George Lau, MD 852-28613777 email@example.com|